BACKGROUND OF THE INVENTION
1. Field of the Invention
[0001] The present invention relates in general to drug delivery devices used to deliver
ionic medicaments through the skin or other tissues, and, more particularly, to fluid
assemblies and electrode assemblies for the release and delivery of a medicament to
a patient.
2. Background Art
[0002] Drug delivery devices have been known in the art for a number of years. Furthermore,
drug delivery devices having fluid delivery assemblies for delivering fluid to bioelectrodes
are likewise well known. Conventional fluid delivery assemblies have utilized a number
of methods for the release and delivery of a fluid. These methods include rupturing
one or more pouches contained within a rigid or semi-rigid container, or having a
number of microcapsules within a porous membrane that, when ruptured, release a fluid
through the membrane. These methods include a number of drawbacks, including the necessity
for several separate structures, and the additional and sometimes cumbersome structures
necessary to direct the flow of the released fluid.
[0003] Iontophoretic drug delivery devices, a subset of drug delivery devices, have also
been known in the art for some time. These devices provide the electromotive force
that drives an ionic drug from a pad or sponge containing the drug through the skin
or other surface of a patient. Conventional drug delivery devices generally include
a single active electrode and a single passive electrode, completing the circuit once
the two are attached to the tissue of a patient. However, this electrode alignment
has the drawback of requiring either high electric fields to deliver sufficient drug
to the area, resulting in unwanted sensation and burning, or lower electric fields
and resultantly lower delivery rates of the drug. Therefore, the use of a single set
of an active and a passive electrode often results in unwanted electric field concentration
or in decreased electrode performance.
[0004] The conventional iontophoretic devices additionally utilize well known methods of
retaining a medicament in the drug delivery device, including gel sponges and disbursement
pads. These media retain a medicament until placed next to skin/tissue and subjected
to an electric current. However, these media can leak or seep fluid once applied,
causing a short-circuit of the entire device.
[0005] It is therefore an object of the present invention to provide a simple and effective
means for releasing a fluid from a reservoir, and then directing the flow of that
fluid in a predetermined direction.
[0006] It is a further object of the present invention to provide consistent and optimum
iontophoretic delivery of a drug while minimizing the negative effects of a concentrated
electric field.
[0007] It is additionally an object of the present invention to provide a simple and effective
structure for the prevention of migration of the medicament in the device out of the
delivery pad towards the passive electrode.
[0008] It is also an object of the present invention to provide an integrated device and
method, utilizing the above advantages, for the delivery of a fluid to a drug delivery
device, and then to the tissue of a patient, while maintaining the integrity of the
electrodes and the medicament.
[0009] These and other objects of the invention will be apparent to those having ordinary
skill in the art in light of the associated specification, claims and drawings.
SUMMARY OF THE INVENTION
[0010] The present invention is directed to a fluid reservoir for use with a drug delivery
device. The fluid reservoir has a sealed fluid chamber having a top surface and a
bottom surface, and a cavity therebetween. The cavity is at least partially defined
by at least one seal. The cavity serves to house a fluid therewithin. The invention
further includes means for fracturing at least a portion of the at least one seal,
and, means for controllably releasing a liquid, positionable within the cavity, out
of the cavity.
[0011] In another preferred embodiment, the at least one seal comprises a first seal and
a second seal, further defining the cavity therebetween, and, the fracturing means
is associated with the first seal. The fluid reservoir may be oval in shape, and the
first and second seals are concentric with one another. However, it is contemplated
that the fluid reservoir be configured in numerous geometrical patterns, such as circles,
rectangles, and squares.
[0012] In yet another preferred embodiment, one of the top and bottom surfaces of the fluid
reservoir includes means for directing released fluid to a region adjacent the fluid
reservoir, wherein the directing means comprises at least one slit in the associated
top or bottom surface. Additionally, at least a portion of the top surface of the
fluid reservoir is deformable upon exertion of a force.
[0013] In still another preferred embodiment, at least one seal comprises at least a first
region of attachment and a second region of attachment. The fracturing means comprises
the first region of attachment having a weaker attachment than the second region of
attachment.
[0014] In another preferred embodiment, the control means comprises at least a portion of
the seal having a pinch-like configuration.
[0015] This present invention is also directed to an electrode assembly for use with a drug
delivery device. The electrode assembly comprises means for carrying a medicament;
an active electrode in electrical communication with the carrying means; at least
two passive electrodes; and means for securing the electrode assembly to a surface
of a patient. Upon securement, the active electrode is distally spaced from the at
least two passive electrodes, and the at least two passive electrodes are distally
spaced from each other.
[0016] In such a preferred embodiment of the invention, the at least two passive electrodes
are spaced on opposite sides of the active electrode, relative to one another. The
medicament carrying means may comprise a dispersive pad, such as a gel sponge.
[0017] In another preferred embodiment, the electrode assembly further includes a medicament
migration barrier region adjacent the medicament carrying means. The medicament migration
barrier may be spaced from the dispersive pad, creating a moat-like region therebetween.
[0018] In another preferred embodiment, the electrode assembly further comprises a separator
pad having a surface, and the securing means comprises at least a portion of the surface
of the separator pad having an adhesive. The separator pad may additionally comprise
means for preventing migration of a medicament. The separator pad may be positioned
adjacent the active electrode and at least one of the at least two passive electrodes.
[0019] In a preferred embodiment, the securing means comprises an electrically conductive
adhesive attached to the at least two passive electrodes. Such an adhesive may comprise
Gum Karaya.
[0020] In another embodiment, the electrode assembly comprises at least one fluid reservoir
capable of retaining a medicament, and an assembly tray. The assembly tray is configured
to hold the electrode assembly and the at least one fluid reservoir. The assembly
tray comprises a substantially rigid surface which is capable of deformation upon
application of a force.
[0021] In such a preferred embodiment the at least one fluid reservoir comprises at least
two fluid reservoirs.
[0022] The present invention is also directed to an electrode assembly for use with a drug
delivery device, comprising means for carrying a medicament; means for preventing
the migration of a medicament spaced from the carrying means, creating a moat region
therebetween; an active electrode in electrical communication with the carrying means;
at least one passive electrode; and means for securing the electrode assembly to a
surface of a patient.
[0023] In another embodiment, the invention includes at least two passive electrodes. Preferably,
the securing means secures the electrode to a surface of a patient with the active
electrode distally spaced from the at least two passive electrodes, and the at least
two passive electrodes are distally spaced from one another.
[0024] The invention also discloses an electrode assembly for use with a drug delivery device,
comprising means for carrying a medicament; an active electrode, in electrical communication
with the carrying means, comprising a silver conductive element; at least one passive
electrode, comprising a carbon conductive element; and means for securing the electrode
assembly to a surface of a patient. Preferably, the at least one passive electrode
comprises at least two passive electrodes. It is also preferred that at least two
passive electrodes are spaced on opposite sides of the active electrode, relative
to one another.
[0025] In another embodiment of the invention, the electrode assembly further comprises
a fluid reservoir capable of retaining a medicament, and an assembly tray. The assembly
tray is configured to hold the electrode assembly and the fluid reservoir, and comprises
a substantially rigid surface. The rigid surface is capable of deformation upon application
of a force.
[0026] The present invention additionally discloses an iontophoretic drug delivery apparatus,
comprising a fluid reservoir capable of retaining a medicament. The fluid reservoir
comprises a sealed fluid chamber having a top surface and a bottom surface, and a
cavity therebetween, the cavity being at least partially defined by at least one seal.
The cavity serves to house a fluid therewithin. The apparatus also includes means
associated with the sealed fluid chamber for enabling release of a fluid therefrom;
and, means for controllably releasing a liquid, positionable within the cavity, out
of the cavity. An electrode assembly is associated with the fluid reservoir and comprises
means for carrying a medicament; an active electrode in electrical communication with
the carrying means; at least two passive electrodes; means for preventing the migration
of a medicament, adjacent the active electrode and the at least two passive electrodes,
spaced from the active electrode (so as to create a moat-like region therebetween)
and, means for securing the electrode assembly to a surface of a patient, wherein
upon securement the active electrode is distally spaced from the at least two passive
electrodes, and the at least two passive electrodes are distally spaced from each
other. A tray assembly is configured to hold both the fluid reservoir and the electrode
assembly in their relative positions. The tray assembly comprises a substantially
rigid surface, capable of deformation upon application of a force. Furthemore, the
apparatus includes means for storing the completed assembly.
[0027] The invention also discloses a method for releasing a fluid from a fluid reservoir.
The method comprises the steps of a) depressing at least a portion of a sealed fluid
chamber, wherein the fluid chamber includes a cavity at least partially defined by
at least one seal, having a fluid therewithin; b) fracturing at least a portion of
the at least one seal; and, c) controllably releasing the fluid out of the cavity.
[0028] The fluid chamber may additionally comprise a top surface and a bottom surface. Accordingly,
the step of depressing comprises deforming at least a portion of the top surface.
[0029] In a preferred embodiment of the invention, the at least one seal comprises a first
seal and a second seal, and the step of fracturing at least one seal comprises the
step of fracturing the first seal. It is contemplated that the at least one seal have
a pinch-like configuration.
[0030] In yet an additional embodiment of the invention, the at least one seal comprises
a first region of attachment and a second region of attachment and the step of fracturing
comprising fracturing at least a portion of the first region of attachment.
[0031] The present invention is further directed to a method for iontophoretically administering
a medicament to a patient using an electrode assembly. The method comprises the steps
of a) impregnating a means for carrying a medicament, associated with an electrode
assembly, with a medicament; and b) applying the electrode assembly to a surface of
a patient, wherein the electrode assembly comprises an active electrode and at least
two passive electrodes. The step of applying comprises the steps of c) placing the
active electrode in distally spaced relation to the at least two passive electrodes,
and placing the at least two passive electrodes in distally spaced relation to one
another; and d) applying an electrical potential across the active electrode, the
surface of the skin, and the at least two passive electrodes in such a way so as to
drive the impregnated medicament from the carrying means and into the skin.
[0032] The invention still further discloses a method for iontophoretically applying a medicament
to a patient, comprising the steps of a) applying a force to a top surface of a fluid
reservoir, associated with an electrode assembly, the fluid reservoir having a cavity
and a fluid contained therein; b) compressing at least a portion of the top surface
of the fluid reservoir; c) fracturing at least a portion of a first region of at least
one seal of the fluid reservoir while substantially maintaining the integrity of a
second region of the at least one seal; d) releasing the fluid from the cavity within
the fluid reservoir; e) directing the flow of the released fluid, out of the cavity,
and onto a medicament carrying means; and, f) iontophoretically administering the
medicament to a patient using the electrode assembly.
[0033] Additionally, the invention is also directed to a method for iontophoretically applying
a stored medicament to a patient, comprising the steps of a) removing a tray assembly
from storage, the tray assembly comprising a substantially rigid shell, configured
to hold a fluid reservoir and an electrode assembly in relative positions, and a removable
cover; b) applying force to a portion of the shell, associated with the fluid reservoir;
c) compressing at least a portion of the shell into a top surface of the fluid reservoir;
d) fracturing at least a portion of a first region of at least one seal of the fluid
reservoir, while substantially maintaining the integrity of a second region of the
at least one seal; e) releasing a fluid from a cavity within the fluid reservoir;
f) directing the flow of a released fluid out of the cavity, and onto a medicament
carrying means, a part of the electrode assembly; g) removing the electrode assembly
from the tray assembly; h) applying the electrode assembly to a surface of a patient,
wherein the step of applying further comprises placing an active electrode, in electrical
communication with the medicament carrying means, in distally spaced relation to at
least two passive electrodes; i) placing the at least two passive electrodes in distally
spaced relation to one another; and j) iontophoretically administering the fluid to
a patient using the electrode assembly.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034]
Fig. 1 of the drawings is an exploded view of the tray assembly and the pouch assembly;
Fig. 2 of the drawings is an exploded view of the electrode assembly and the separator
pad;
Fig. 3 of the drawings is an exploded view of the iontophoretic drug delivery device
storage device before sealing;
Fig. 4 of the drawings is a top plan view of the tray assembly and the electrode assembly;
Fig. 5 of the drawings is a top view of the inner seal of the pouch apparatus;
Fig. 6 of the drawings is a longitudinal cross-sectional view of the storage device;
Fig. 7 of the drawings is a transverse cross-sectional view of the storage device;
Fig. 8 of the drawings is an exploded view of the tray assembly and the pouch assembly
with two pouch assemblies;
Fig. 9 of the drawings is an exploded view of the electrode assembly and the separator
pad for use with two pouch assemblies;
Fig. 10 of the drawings is a perspective view of an alternative design of the pouch
assembly; and
Fig. 11 of the drawings is a perspective plan view of an alternative design of the
pouch assembly.
BEST MODE OF THE INVENTION
[0035] Referring now to Figs. 1 and 2, iontophoretic drug delivery device storage apparatus
20 is shown as comprising tray assembly 22, pouch assembly 24, separator pad 28 and
electrode assembly 26. When properly assembled, storage apparatus 20 enables the secure
and safe storage, transportation, and handling of the enclosed items. Additionally,
and as will be discussed further below, once tray assembly 22 is opened, electrode
assembly 26 can be removed, and operatively placed upon a patient for the iontophoretic
administration of a medicament.
[0036] Tray assembly 22 is shown in Fig. 6 as comprising outer shell 30 having three distinct
recessed areas, first recess 38, second recess 40, and third recess 42. These recessed
areas are configured so as to enable the secure insertion and containment of pouch
assembly 24, separator pad 28, and electrode assembly 26 in their relative positions.
First recess 38, relatively the deepest of the three, is configured in substantially
the same shape as pouch assembly 24. Second recess 40, the middle section, is configured
relatively wider than first recess 38. It is configured specifically so as to receive
separator pad 28, and to hold that member in a secure position relative to pouch assembly
24. The third and final recessed area is the shallowest of the three. It is the broadest
recessed area, and preferably runs nearly the entire length of outer shell 30. Third
recess 42 is configured to receive and hold electrode assembly 26. As will be discussed
further, third recess 42 additionally includes extended area 44, as can best be seen
in Fig. 4. This area provides a storage location for lead wires 84 of electrode assembly
26.
[0037] Although the above discussion is focused on outer shell 30 having a specified number
of recessed areas for insertion of the three.components, it is additionally contemplated
that other configurations could accomplish the same functions of secure retention
of the elements in their appropriate relative positions, while not deviating from
the ideas disclosed within this application. For example, outer shell 30 could have
only one or two recessed areas, with the various components being configured to maintain
proper alignment within tray assembly 22. Additionally, it is also contemplated that
more than three recessed areas are acceptable, as would be contemplated by one of
ordinary skill in the art.
[0038] Preferably, and as can be seen in Fig. 1, outer shell 30 additionally includes rim
32 along the circumference of the upper portion of tray assembly 22 and adjacent third
recess 42. Rim 32 is configured to provide an area of attachment for cover 34 (shown
in Fig. 3). In final, preferred form, pouch assembly 24, separator pad 28, and electrode
assembly 26 are all inserted into their relative locations in tray assembly 22, and,
thereafter, cover 34 is attached to rim 32, sealing iontophoretic device therein for
safe and secure storage and handling.
[0039] Outer shell 30 of tray assembly 22 additionally aids in the safe and secure storage
and handling of pouch assembly 24, separator pad 28, and electrode assembly 26. In
order to do so, outer shell 30 is preferably constructed from a rigid or semi-rigid
material to protect the retained contents. This rigid or semi-rigid material is preferably
a plastic material, such as polypropylene, but may be constructed from any number
of similar materials known in the art.
[0040] Additionally, the rigid to semi-rigid outer shell 30 of tray assembly 22 should include
at least a portion 36 that is deformable upon the application of a force. Generally,
outer shell 30 may be formed from a material that is substantially inflexible to the
application of force. However, it is necessary that outer shell 30 have at least a
portion that is capable of deformation upon application of a force. Deformable portion
36 may be constructed from the same material as the rest of the shell, with a lesser
cross-linking density, or deformable portion 36 may even be constructed from a different
material altogether. In any case, deformable portion 36 of outer shell 30 must allow
for deformation of the shell upon application of a predetermined force.
[0041] Deformable portion 36 may be included on any number of places on outer shell 30.
For example, the portion 36 may be a part of the entire outer shell 30, or may include
only sections of the entire outer shell. Preferably, deformable portion 36 of outer
shell 30 may be associated with only the first recessed area, corresponding substantially
with the shape of the pouch assembly 24. This configuration provides for the functionality
of being able to compress outer shell 30 at or around the inserted pouch assembly
24, and still provides for the protection of the remainder of the components of storage
device 20, such as pouch assembly 24, electrode assembly 26, and separator pad 28.
[0042] Pouch assembly 24 is shown in Fig. 1 prior to insertion into tray assembly 22. Pouch
assembly 24 comprises top surface 50, bottom surface 52, outer seal 54, and inner
seal 56. Top surface 50 and bottom surface 52 are connected at both the outer seal
54 and inner seal 56 to create sealed fluid chamber 58. Sealed fluid chamber 58 is
capable of holding a liquid, gel, or other fluidic material for later release.
[0043] As pictured, pouch assembly 24 is shaped in a generally oval shape. Alternative configurations
can be seen in Figs. 10 and 11, showing pouch assembly 24 as generally circular and
generally square. Any number of pouch configurations are similarly possible for pouch
assembly 24, as would be readily understood by one of ordinary skill in the art.
[0044] Top 50 and bottom 52 surfaces of pouch assembly 24 are preferably made of an inexpensive,
non-reactive, and easily formable material, such as aluminum. The choice of material
allows for the top 50 and bottom 52 surfaces to be substantially non-reactive with
whatever fluid is contained within sealed fluid chamber 58, while still allowing any
number of choices with respect to the shape and configuration of pouch assembly 24.
The material chosen should, however, be resistant to minor applications of force.
In order to maintain the integrity of pouch assembly 24 over periods of time, including
periods of time where pouch assembly 24 may be stored in a stacked configuration,
pouch assembly 24 should not burst unless directed and intentional force is applied
to at least one of the top 50 or bottom 52 surfaces.
[0045] Additionally, it is necessary to ensure that the material selected for top surface
50 and bottom surface 52 be non-reactive with the fluid to be contained in fluid chamber
58. In order to do so, it is preferable to use a coated material. For example, if
aluminum is selected as the material for the top and bottom surfaces of pouch assembly
24, it is preferable to coat the material with a protective coating such as an ethylene
ionomer. Specifically, the preferred material for the top and bottom surfaces comprise
a thin layer of aluminum coated with a small amount of Surlyn™ sealant, an ethylene
ionomer. With this configuration, the pouch material is thin, durable, non-reactive
and relatively inexpensive.
[0046] Top surface 50 additionally comprises depressable area 60. Depressable area 60 is
deformable upon application of a force. Preferably, force is applied to depressable
area 60 in the direction of bottom surface 52, deforming top surface 50 towards bottom
surface 52, and placing force upon the fluid contained within the sealed fluid chamber
58.
[0047] Depressable area 60 preferably coincides with the entire top surface 50 of pouch
assembly 24, allowing force application at any point along the surface to transfer
force into the fluid itself. Additionally, a smaller area of top surface 50 may be
depressable, with the rest of the top surface remaining rigid or semi-rigid. The area
of depressability is arbitrary, in fact, except for that some area of top surface
50 must be capable of deformation.
[0048] Similarly, and as would be obvious to one having ordinary skill in the art, bottom
surface 52 may have one or more areas that are depressable. In that case, application
of force to depressable area 60 of bottom surface 52 would deform bottom surface 52
in the direction of top surface 50, placing a force upon the fluid contained in sealed
fluid chamber 58.
[0049] Top and bottom surfaces 50, 52, respectively, are connected at outer and inner seals,
54, 56, respectively, so as to seal fluid chamber 58 between the top and bottom surfaces.
The outer and inner seals, 54, 56, are preferably created through standard welding
techniques, by placing the top and bottom surfaces next to one another, and applying
directed pressure or heat at the desired seal location. Thus, the top and bottom surfaces
are unitized at that point.
[0050] It is also contemplated, however, that an additional substance could be used to seal
the top and bottom surfaces together. For example, an adhesive or a stitching process
can be used which would render the area between the top and bottom surfaces sealed.
Preferably, however, any additional substances that are included in pouch assembly
24 should be non-reactive relative to both the fluid contained in sealed chamber 58
and the top and bottom surfaces themselves.
[0051] As can be seen in Fig. 1, as well as in Figs. 10 and 11, outer seal 54 is of somewhat
different configuration than inner seal 56. Specifically, outer seal 54 preferably
comprises a substantially continuous seal around the circumference of the pouch assembly
24. Outer seal 54 is therefore preferably of uniform thickness and strength around
that entire area, ensuring no one area is weaker than another.
[0052] On the other hand, inner seal 56, shown best in Fig. 5, comprises at least two different
seal areas, and additionally comprises pinch point 62. In contrast with outer seal
54, inner seal 56 is deliberately formed with one region having a weaker connection
than the other regions. For example, region one 64 of inner seal 56 is formed in substantially
the same manner as outer seal 54. Region one 64 is of constant thickness and strength,
leaving no one area within the region weaker than another. Region two 66 is similarly
uniform. Region two 66 is formed from a different weld or sealing technique than region
one 64, leaving the seal at region two 66 relatively weak when compared to the seal
at region one 64 and in outer seal 54.
[0053] Region two 66 additionally comprises pinch point 62. Pinch point 62, as will be described
in more detail below, acts as a focus for pressure applied to top surface 50 or bottom
surface 52. If pressure is applied to the top or bottom surfaces, region two 66 of
inner seal 56 will break first, specifically at pinch point 62, ensuring that fluid
released from sealed fluid chamber 58 will be released in the desired direction.
[0054] Pinch point 62 is shown in Fig. 5 in its preferred formation, that of an inverted
"V" shape. This "V" shape allows for the force applied to top surface 50 or bottom
surface 52 to be directed specifically at one point. Any number of structures, however,
will fulfill this purpose without deviating from the ideas embodied by this invention.
[0055] Pouch assembly 24 is shown in its preferred configuration, with one outer seal 54
and one inner seal 56, creating a sealed fluid chamber 58 therebetween. Additionally,
the invention is shown as preferably having inner seal 56 comprising at least two
seal regions, and a pinch point 62. In this configuration, outer seal 54 will be substantially
uniform and continuous, while inner seal 56 is not.
[0056] It is additionally contemplated that other, similar configurations would provide
the same or similar functions as are satisfied with the above preferred configuration.
For example, outer seal 54 could have one or more regions of varying seal strength,
and could have a pinch point 62 similar to inner seal 56. In that case, force applied
to either top surface 50 or bottom surface 52 could pierce either inner seal 56 or
outer seal 54. Similarly, inner seal 56 could instead be substantially uniform and
continuous, ensuring it would remain intact while outer seal 54 was ruptured. Lastly,
it is possible that there is no inner seal 56, with outer seal 54 running the length
of the circumference of top surface 50 and bottom surface 52, forming a sealed fluid
chamber 58 therein. All of these embodiments are contemplated by the present invention,
and fall within the scope of the protection offered by this application.
[0057] As shown in Fig. 5, contained within inner seal 56 is release reservoir 68, in which
are located fluid delivery slits 69. Fluid delivery slits 69 are located in and through
top surface 50 or bottom surface 52 to provide a passageway through the two surfaces.
The slits are located at or near the center of release reservoir 68, which is surrounded
by inner seal 56. Since inner seal 56 marks the boundary of sealed fluid chamber 58,
and sealed fluid chamber 58 is filled, preferably, with a fluid, the area surrounding
inner seal 56 is raised in comparison with release reservoir 68. Therefore, release
reservoir 68 acts as a valley into which the fluid released from sealed fluid chamber
58 will flow.
[0058] As can be seen in Fig. 1, pouch assembly 24 also includes sealant ring 67. Sealant
ring 67 secures pouch assembly 24 within first recess 38 of tray assembly 22. When
tray assembly 22 is opened for removal of electrode assembly 26, sealant ring 67 ensures
pouch assembly 24 will remain with tray assembly 22, allowing unencumbered manipulation
and use of electrode assembly 26 and separation pad 28. Sealant ring 67 is constructed
from the same or similar material as pouch assembly 24, and is secured to tray assembly
22 using a non-reactive permanent adhesive. Therefore, upon sealing pouch to tray
assembly 22, and upon subsequent release of fluid from pouch assembly 24, there are
no side-reactions or byproducts created by the presence of sealant ring 67.
[0059] A preferred configuration of storage device 20 is shown in Fig. 8. As can be seen,
storage device 20 comprises tray assembly 22, and at least two pouch assemblies 24,
24'. In this embodiment, the tray assembly 22 comprises much of the same structure
as in Fig. 1, except that the layered structure described above is duplicated for
a second pouch assembly 24'. As shown, at least two pouch assemblies 24, 24' are placed
within the respective recesses of the tray assembly 22, and sealed therein with sealant
ring 67. As will be discussed further below, the inclusion of two or more pouch assemblies
24, 24' within storage device 20, along with electrode assembly 26, provides for advantageous
delivery of one or more fluids to electrode assembly 26 for later iontophoretic application.
[0060] Electrode assembly 26 is shown in Fig. 2 as comprising backing pad 70, wiring assembly
72, gum karaya pads 74, and medicament pad 76. Additionally, Fig. 2 shows the proper
placement and inclusion of pouch assembly 24, discussed above, and separator pad 28,
discussed below, within storage device 20 and adjacent electrode assembly 26. Electrode
assembly 26, once properly contacted with the fluid contained in pouch assembly 24
or assemblies, can be removed from storage device 20, and applied to an arm, leg,
or other surface of a patient for the iontophoretic delivery of a drug to that area.
[0061] Backing pad 70 is shown in Fig. 2 as a thin, flexible, water resistant base for wiring
assembly 72, medicament pad 76, gum karaya pads 74 and separator pad 28. Backing pad
70 is preferably constructed from a thin portion of polyurethane material, formed
in substantially the same shape as the imprint of the electrode assembly 26. The polyurethane
additionally includes an adhesive on one side to adhere to the wiring assembly 72,
and to portions of separator pad 28 and gum karaya pads 74, as will be discussed further
below. The structures adhere to the exposed portions of backing pad 70 permanently,
so that later manipulation and application of electrode assembly 26 to the surface
of a skin is aided.
[0062] Wiring assembly 72 can be seen in Fig. 2 as comprising active electrode 78, two passive
electrodes 80, connecting wires 82, and lead wires 84. Active electrode 78 is depicted
as a flat, oval-shaped metallic conductive element located directly under medicament
pad 76. Active electrode 78 is connected through connecting wires 82 to lead wires
84 for later connection to a power source (not shown). Active electrode 78, after
placing both it and the passive electrodes 80 on a patient and attaching a power source,
provides an electric flux field across medicament pad 76 that drives an ionic medicament
out of the pad and into the skin of a patient. In order to ensure complete coverage
of medicament pad 76 by the electric flux field, active electrode 78 is formed so
as to substantially correspond with the shape of medicament pad 76. Active electrode
78 may be constructed from any number of conducting materials as would be readily
understood by those having ordinary skill in the art.
[0063] Passive electrodes 80 are shown as flat, semi-circular metallic conductive elements
on opposite sides of active electrode 78. Passive electrodes 80 are connected to connecting
wires 82, which in turn are connected to lead wires 84 for later connection to a power
source. The passive electrodes 80 do not provide an electric flux to drive medicament
into the skin of a patient. Instead, the passive electrodes 80 complete the electric
circuit through the skin, providing for the transfer of electrons back to the power
source. Passive electrodes 80 do have an electric field associated with them, however.
The inclusion of two passive electrodes 80, and the placement of the electrodes on
opposite sides of the active electrode 78, allows for this electric field to be spread
out over a larger skin area. Since electric fields can cause irritation and discomfort
when too concentrated, the spacing as well as the reduction in the size of the electrode
enables higher flux through the active electrode 78 while reducing the occurrence
of concentrated electric field irritations.
[0064] Passive electrodes 80 may be constructed from any number of conducting materials,
similar to the active electrode 78. However, it is preferable to construct the passive
electrodes 80 from a carbon conductive element.
[0065] Connecting wires 82 connect passive electrodes 80 to one lead wire 84', and active
electrode 78 to the other lead wire 84". Lead wires 84 extend beyond the coverage
provided by backing pad 70 in order to allow outside connection of electrode assembly
26 to a current source. Lead wires 84 and connecting wires 82 are conventional, as
would be known in the art.
[0066] The completed electrode assembly 26 can be seen in its proper orientation within
tray assembly 22 in Fig. 4. Tray assembly 22 is shown with its three recessed areas,
and also with extended area 44 of the third recess 42. Electrode assembly 26 fits
properly in tray assembly 22 with medicament pad 76 and sealant member in second recess
40, and with the rest of electrode assembly 26, including lead wires 84, in third
recess 42.
[0067] Gum karaya pads 74 are shown in Fig. 2 as semi-circular pads having the same or similar
shape as passive electrodes 80. Gum karaya is a conductive, gummy substance that provides
an electrical connection between passive electrodes 80 and the skin of a patient,
while ensuring that passive electrodes 80 and the electrode assembly 26 will not move.
There are other, similar, conductive adhesives that could also fulfill this function.
[0068] Medicament pad 76 is shown in a substantially oval shape, directly over and in line
with active electrode 78. Medicament pad 76 is capable of receiving and retaining
a medicament or other fluid for eventual dispersion through iontophoresis. Medicament
pads 76 have been known in the art for some period of time, and may include such structures
as a sponge, a disbursement pad, or a gel sponge. In each of these cases, medicament
pad 76 may contain a medicament already, and merely be waiting for hydration from
an outside source, or the medicament pad 76 can be dry.
[0069] The shape of medicament pad 76 can be altered to fit any desired application area.
For example, if medicament pad 76 will be used to apply medicament to a circular-shaped
area, medicament pad 76 can be altered to that shape. However, such alterations are
a design choice that, preferably, incorporates the design of both active electrode
78 and pouch assembly 24. In other words, pouch assembly 24, medicament pad 76, and
active electrode 78 are all preferably of the same cross-sectional shape. Therefore,
the release of the fluid from pouch assembly 24 ensures complete coverage of medicament
pad 76, and also complete flux of the medicament out of the pad once an electric field
is applied.
[0070] Separator pad 28 is shown in Fig. 2 as a substantially oval structure having a cut-out
90 oval in its center. Additionally, separator pad 28 has wings 92 extending along
its lateral sides. Cut-out 90 of separator pad 28 is formed so as to substantially
correspond with the approximate shape of medicament pad 76. Separator pad 28 is adhered
to connecting wires 82 of electrode assembly 26 and backing pad 70 of electrode assembly
26 in such a way as to maintain the spacing between separator pad 28, passive electrodes
80 and medicament pad 76 through usage of electrode assembly 26. The placement adjacent
to, but spaced apart from medicament pad 76, creates moat region 94. Moat region 94,
in turn, allows separator pad 28 to prevent any migration of medicament out of medicament
pad 76 and active electrode 78 area toward passive electrodes 80, and similarly to
prevent any electrical bleed through from active electrode 78 to passive electrodes
80. In both the cases of migrating medicament and electrical bleed through, separator
pad 28 ensures that electrode assembly 26 will not short circuit itself, thus increasing
the medicament flux across the skin of a patient.
[0071] In addition to preventing unwanted fluid and electrical transfers from medicament
pad 76, it is similarly undesirable that fluid or other substance migrate from passive
electrodes 80 and gum karaya pads 74 towards active electrode 78. Because of the nature
of gum karaya, and as would be the problem with other, similar adhesives, there is
an inherent fluidity to its makeup. Therefore, it is desirable to maintain the separation
of the gum karaya and passive electrodes 80 from medicament pad 76. As such, separator
pad 28 additionally includes wings 92 for maintaining the separation and integrity
of gum karaya and medicament pad 76.
[0072] The above-mentioned functions of separator pad 28 presume that the properties of
separator pad 28 allow it to act as both a fluid barrier and an electrical barrier.
Separator pad 28 may be constructed from any number of materials capable of providing
these functions. However, and preferably, the present invention includes separator
pad 28 constructed from a polyurethane foam with a moderate thickness of approximately
1 mm.
[0073] In addition to the barrier functions of separator pad 28, separator pad 28 may also
help the electrode assembly 26 to adhere to the skin of a patient. Since separator
pad 28 is fixedly attached to wiring assembly 72 and backing pad 70 of electrode assembly
26, adding an adhesive to the exposed side of separator pad 28 enables the electrode
assembly 26 to be securely affixed in a single position. However, it is important
that the adhesive chosen be able to release without damaging the patient.
[0074] It is important to note that separator pad 28 is shown in Fig. 2 as comprising a
complete oval surrounding medicament pad 76. It should also be noted, however, that
portions or arcs of a pad may substantially serve the same purpose. Since fluid migration
and electrical bleed is most undesirable in the direction of passive electrodes 80,
separator pad 28 may comprise arcs or sections located between passive electrodes
80 and medicament pad 76. It is additionally contemplated that separator pad 28 could
completely surround passive electrodes 80, leaving medicament pad 76 laterally open.
[0075] Storage device 20 is properly assembled utilizing all of the above structures. First,
tray assembly 22 is provided without cover 34. Next, pouch assembly 24 or assemblies
(as seen in Figs. 8 and 9) are inserted into tray assembly 22, and sealed therein
with sealing ring. Next, electrode assembly 26 with separator pad 28 attached thereto
is inserted into tray assembly 22, with medicament pad 76 being substantially aligned
with pouch assembly 24. Electrode assembly 26 is essentially inserted upside-down,
with medicament pad 76 contacting pouch assembly 24, wiring assembly 72 and gum karaya
pads 74 at about the same level, and backing pad 70 on top, protecting the entire
electrode assembly 26. Thereafter, cover 34 is attached to rim 32 of tray assembly
22, and storage assembly is ready for safe handling and shipping.
[0076] In operation, the already sealed storage device 20 is first removed from storage.
Storage device 20 preferably already contains the desired components that are to be
applied to the skin of a patient. Any number of pre-included fluids can be contained
in the storage device 20, and specifically in pouch assembly 24. For example, pouch
assembly 24 could contain an ionic medicament, such as is commonly used in iontophoretic
drug delivery applications. Additionally, pouch assembly 24 could contain a hydrating
compound which, when delivered to an appropriately drug-impregnated medicament pad
76, hydrates and activates a similar ionic medicament. In either case, the storage
device 20 will have the necessary components preinstalled. Therefore, after removal
of the storage device 20, an operator places storage device 20 with cover side down
on a flat surface, or any other surface that will allow easy manipulation. Thereafter,
the following steps are taken:
First, force is applied to deformable portion 36 of outer shell 30, deforming that
portion of outer shell 30 towards and into top surface 50 of pouch assembly 24. Once
deformable portion 36 and top surface 50 contact one another, force is transferred
into top surface 50, towards bottom surface 52. This force compresses sealed fluid
chamber 58, pushing fluid towards inner seal 56 of pouch assembly 24. Fluid ruptures
region two 66 of inner seal 56, leaving region one 64 intact. Specifically, region
two 66 is ruptured at pinch point 62, ensuring the directed release of the fluid from
within sealed fluid chamber 58, out of pouch assembly 24.
Second, fluid flows out of sealed fluid chamber 58, through pinch point 62 of inner
seal 56, and onto release reservoir 68. Release reservoir 68 receives the fluid, and
directs it through fluid delivery slits 69 located at or near the center area of release
reservoir 68. Fluid travels through fluid delivery slits, and onto medicament pad
76 located adjacent pouch assembly 24.
[0077] Depending upon what type of fluid is contained in pouch assembly 24, the contacting
of the fluid with medicament pad 76 may merely saturate that pad 76 with an ionic
medicament, as described above, or the fluid may hydrate an already impregnated medicament
pad 76. Either way, the medicament contained in the medicament pad 76 or in the pouch
assembly 24 does not become ready for application until the fluid is released from
pouch assembly 24 and contacted with medicament pad 76.
[0078] Once medicament pad 76 is sufficiently hydrated, the operator removes cover 34 from
rim 32 of tray assembly 22. This exposes backing pad 70 of electrode assembly 26.
The operator thereafter removes electrode assembly 26 from tray assembly 22, leaving
pouch assembly 24 contained within tray assembly 22, but removing electrode assembly
26 and sealing pad 28 with backing pad 70.
[0079] After removal, electrode assembly 26 is placed on the skin of a patient with gum
karaya pads 74 and the adhesive portions of separator pad 28 facing down. Thereafter,
power source (not shown) or controller (not shown) is attached to lead wires 84 in
the appropriate order to create a medicament flux across the surface of a patient.
For example, the positive side of a voltage drop should be applied to the active electrode
if the hydrated medicament or the medicament delivered from the pouch assembly is
a positively charged ionic species. Once affixed and connected, iontophoretic delivery
of the medicament from the medicament pad 76 to the skin of a patient is achieved.
1. An electrode assembly for use with a drug delivery device, comprising:
means for carrying a medicament (76);
an active electrode (78) in electrical communication with the carrying means (76);
at least one passive electrode (80);
a separator pad (28) surrounding the carrying means (76);
a moat region (94) disposed between the separator pad (28) and the carrying means
(76) that prevents migration of the medicament between the carrying means (76) and
the at least one passive electrode (80); and
means (74) for securing the electrode assembly to a surface of a patient.
2. The electrode assembly according to claim 1, wherein the at least one passive electrode
(80) comprises at least two passive electrodes (80).
3. The electrode assembly according to claim 2, wherein the securing means (74) secures
the electrode (80) to a surface of a patient with the active electrode (78) distally
spaced from the at least two passive electrodes (80), and the at least two passive
electrodes (80) are distally spaced from one another.
4. The electrode assembly according to claim 2 or 3, wherein the at least two passive
electrodes (80) are spaced on opposite sides of the active electrode (78), relative
to one another.
5. The electrode assembly according to any of claims 1 to 4, wherein the medicament carrying
means (76) comprises a dispersive pad (76).
6. The electrode assembly according to any of claims 1 to 5, wherein the carrying means
(76) comprises a gel sponge.
7. The electrode assembly according to any of claims 1 to 6, wherein the separator pad
(28) comprises a surface, and the securing means (74) comprises at least a portion
of the surface of the separator pad (28) having an adhesive.
8. The electrode assembly according to any of claims 1 to 7, wherein the securing means
(74) comprises an electrically conductive adhesive (74) attached to the at least one
passive electrode (80).
9. The electrode assembly according to claim 8, wherein the electrically conductive adhesive
(74) comprises Gum Karaya (74).
10. The electrode assembly according to any of claims 1 to 9, wherein the electrode assembly
further comprises at least one fluid reservoir (68) capable of retaining a medicament,
and an assembly tray (22), the assembly tray (22) being configured to hold the electrode
assembly (26) and the fluid reservoir (68); the assembly tray (22) comprising a substantially
rigid surface, the rigid surface being capable of deformation upon application of
a force.
11. The electrode assembly according to any of claims 1 to 10, wherein the at least one
fluid reservoir (68) comprises at least two fluid reservoirs (68).
12. A method for making a iontophoretic drug delivery apparatus ready for use, comprising:
applying a force to a top surface of a fluid reservoir, associated with an electrode
assembly, the fluid reservoir having a cavity and a fluid contained therein;
compressing at least a portion of the top surface of the fluid reservoir;
fracturing at least a portion of a first region of at least one seal of the fluid
reservoir,
while substantially maintaining the integrity of a second region of the at least one
seal, wherein the first region has a weaker seal connection than the second region;
releasing the fluid from the cavity within the fluid reservoir; and
directing the flow of the released fluid, out of the cavity, and onto a medicament
carrying means, the medicament carrying means being a part of the electrode assembly.
13. The method according to claim12, further comprising:
removing a tray assembly from storage, the tray assembly comprising a substantially
rigid shell, configured to hold a fluid reservoir and an electrode assembly in relative
positions, and a removable cover;
applying a force to a portion of the shell, associated with the fluid reservoir; and
compressing at least a portion of the shell into a top surface of the fluid reservoir.
14. An iontophoretic drug delivery apparatus, comprising:
a fluid reservoir (24) capable of retaining a medicament, the fluid reservoir (24)
comprising:
a sealed fluid chamber (58) having a top surface (50) and a bottom surface (52), and
a cavity (58) therebetween, the cavity (58) being at least partially defined by at
least one seal (54, 56), wherein the cavity (58) serves to house a fluid therewithin;
means (62) associated with the sealed fluid chamber (58) for enabling release of a
fluid therefrom; and
means (68) for controllably releasing a liquid, positionable within the cavity (58),
out of the cavity (58);
an electrode assembly associated with the fluid reservoir (24), comprising:
means for carrying a medicament (76);
an active electrode (78) in electrical communication with the carrying means (76);
at least two passive electrodes (80);
means (28) for preventing the migration of a medicament, adjacent the active electrode
(78) and the at least two passive electrodes (80), spaced from the active electrode
(78), creating a moat region (94) therebetween; and
means (74) for securing the electrode assembly to a surface of a patient, wherein
upon securement the active electrode (78) is distally spaced from the at least two
passive electrodes (80), and the at least two passive electrodes (80) are distally
spaced from each other; and
a tray assembly (22) configured to hold both the fluid reservoir (24) and the electrode
assembly (22) in their relative positions, the tray assembly (22) comprising:
a substantially rigid surface (30, 36), capable of deformation upon application of
a force; and
means (34) for storing the complete assembly.
15. The apparatus of claim 14, wherein the active electrode (78) comprises a silver conductive
element.
16. The apparatus of claim 14, wherein at least one of the at least two passive electrodes
(80) comprises a carbon conductive element.
17. The apparatus according to any of claims 14 to 16, wherein all of the at least two
passive electrodes (80) comprise a carbon conductive element.